Sagimet Biosciences Inc. (SGMT)

NASDAQ: SGMT · IEX Real-Time Price · USD
6.62
-0.11 (-1.63%)
At close: Feb 23, 2024, 4:00 PM
6.55
-0.07 (-1.06%)
After-hours: Feb 23, 2024, 6:59 PM EST

Company Description

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways.

Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne.

The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers.

The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019.

Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

Sagimet Biosciences Inc.
Sagimet Biosciences logo
Country United States
Founded 2006
IPO Date Jul 14, 2023
Industry Biotechnology
Sector Healthcare
Employees 9
CEO David A. Happel

Contact Details

Address:
155 Bovet Rd., Suite 303
San Mateo, California 94402
United States
Phone (650) 561-8600
Website sagimet.com

Stock Details

Ticker Symbol SGMT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $16.00
CIK Code 0001400118
ISIN Number US7867001049
Employer ID 20-5991472
SIC Code 2834

Key Executives

Name Position
Dr. George W. Kemble Ph.D. Executive Chairman of the Board
David A. Happel Chief Executive Officer, President and Director
Dr. Eduardo Bruno Martins DPhil, M.D., Ph.D. Chief Medical Officer
Urs Greber Ph.D. Co-Founder
Dr. Lucas Pelkmans Ph.D. Co-Founder
Joe Oriti Interim Principal Financial Officer
Elizabeth Rozek Esq., J.D. General Counsel and Chief Compliance Officer
Dr. Marie O'Farrell Ph.D. Senior Vice President of Research and Development

Latest SEC Filings

Date Type Title
Feb 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Feb 9, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 5, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Feb 2, 2024 8-K Current Report
Jan 30, 2024 8-K Current Report
Jan 29, 2024 424B4 Prospectus
Jan 25, 2024 EFFECT Notice of Effectiveness